Literature DB >> 11939683

Treatment of sickle cell pain.

Karen F Marlowe1, Michael F Chicella.   

Abstract

Sickle cell disease affects 70,000 Americans who experience an average of 0.8 painful episodes each year. The pathophysiology of sickle cell pain is not completely understood. The disease is characterized by both acute and chronic pain syndromes. Patients with sickle cell pain often encounter barriers to receiving appropriate care, including lack of continuity of care and perceived opiate addiction. Studies describing pharmacotherapy for sickle cell pain have been primarily retrospective and uncontrolled. In analyzing the available literature regarding pathophysiology, assessment, and treatment of sickle cell pain, we found a need for increased practitioner education and intervention to improve the level of care provided to patients with this disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11939683     DOI: 10.1592/phco.22.7.484.33675

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  4 in total

1.  Pharmacological management of sickle cell disease.

Authors:  Uche Anadu Ndefo; Angie Eaton Maxwell; Huong Nguyen; Tochukwu L Chiobi
Journal:  P T       Date:  2008-04

2.  Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia.

Authors:  Mary M Lunzer; Ajay Yekkirala; Robert P Hebbel; Philip S Portoghese
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-26       Impact factor: 11.205

3.  Cognitive-Evaluative Dimension of Pain in Neuropathic Pain Relapse in Sciatica: A Case Report.

Authors:  Tsubasa Kawasaki; Takuya Yada; Masahiro Ohira
Journal:  Medicina (Kaunas)       Date:  2021-06-27       Impact factor: 2.430

4.  Communicating and understanding pain: Limitations of pain scales for patients with sickle cell disorder and other painful conditions.

Authors:  Peter J Collins; Alicia Renedo; Cicely A Marston
Journal:  J Health Psychol       Date:  2020-08-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.